Rent-Seeking: A Traditional PBM’s Pathway to Riches

Rent-seeking is a term economists use to describe an organization’s ability to generate above average economic returns without providing any relative incremental value. Wikipedia may explain it a bit better.

Wikipedia Definition

The simplest definition of rent-seeking is to expend resources in order to gain wealth by increasing one’s share of currently existing wealth instead of trying to create wealth. Since resources are expended but no new wealth is created, the net effect of rent-seeking is to reduce total social wealth. It is important to distinguish between profit-seeking and rent-seeking.

Profit-seeking is the creation of wealth, while rent-seeking is the use of social institutions such as the power of government to redistribute wealth among different groups without creating new wealth. Rent-seeking generally implies extraction of uncompensated value from others without making any contribution to productivity.

The origin of the term refers to gaining control of land or other pre-existing natural resources. In a modern economy, a more common example of rent-seeking would be political lobbying to obtain government benefits/subsidies or to impose burdensome regulations on competitors in order to increase market share.

Studies of rent-seeking focus on efforts to capture special monopoly privileges such as manipulating government regulation of free enterprise competition. The term monopoly privilege rent-seeking is an often-used label for this particular type of rent-seeking. Often-cited examples include a lobby that seeks tariff protection, quotas, subsidies, or extension of copyright law.

How does a traditional PBM employ a rent-seeking methodology?

Most recently, the FTC approved the acquisition of Medco by Express Scripts. The net effect of this purchase is not a creation of new wealth, but instead a reduction in social wealth. The FTC approval of this acquisition will ultimately benefit only the government, Express Script and Medco stockholders.

Patients won’t pay lower prices or see a real difference in their health care outcomes. Retail pharmacies and PBM competitors certainly won’t benefit from this acquisition. History tells us that greed will supersede social responsibility almost 100% of the time. Express Scripts has used the government, with powerful lobbying, to attain near monopolistic privileges.

Some state governments, Texas for example, require PBMs to take on the role of a fiduciary. The problem is that this requirement doesn’t extend to private enterprise. I say it’s a problem not because the government hasn’t interfered, but the opposite. Private enterprise hasn’t exercised its right to require a fiduciary role from their PBM. A transparent PBM, acting as a fiduciary, shares the risk and essentially agrees to be 100% transparent in all of its related business dealings.

This transparency includes sharing third party pricing contracts with pharmacies and rebates from manufacturers. It also includes offering real-time access to MAC price lists for retail and captive mail-order pharmacies. As specialty drugs become a larger part of the dispensing mix, it’s imperative to be fully aware of pricing arrangements between biotechnology companies as well. Here is an example of a typical fiduciary disclosure in a transparent PBM contract.

FIDUCIARY DUTY AND DISCLOSURE
 
“No Name PBM” owes a fiduciary duty to Client and shall discharge that duty in accordance with the provisions set forth herein.
(a) “No Name PBM” shall perform its duties with care, skill, prudence and diligence and in accordance with the standards of conduct applicable to a fiduciary in an enterprise of a like character and with like aims.
(b) “No Name PBM” shall notify Client in writing of any activity, policy or practice of “No Name PBM” that directly or indirectly presents any conflict of interest with the duties imposed by this subsection.
(c) “Covered individual” means a member, participant, enrollee, contract holder or policy holder or beneficiary of a covered entity who is provided health coverage by the covered entity. “Covered individual” includes a dependent or other person provided health coverage through a policy, contract or plan for a covered individual. With regard to the dispensation of a substitute prescription drug for a prescribed drug to a covered individual the following provisions apply.  
Do you have such language in your contract? If you are dealing with a traditional PBM chances are you won’t get it! Traditional PBMs make money by rent-seeking and not by being fully transparent. And if you think health care reform will fix this I urge you to think twice. The solution is to deal only with PBMs willing to sign on as a fiduciary. This begs the question, “how many checks are you willing to cut for traditional PBM services without knowing exactly what you’re getting in return?” 

The Message Out of Express Script’s C-suite is Changing

In a classic bait and switch George Paz, CEO of Express Scripts, has subtly lowered the expectations for the ESI and Medco merger.  As I learn more about George I’m not quite sure what to think about him.  Here is what I’ve gathered thus far.  He’s a shrewd businessman, but not very smart, yet he’s smart enough and frugal.  George is also aggressive, but will change his position faster than Cory Booker if it will bring ESI an advantage.  Sometimes to the detriment of his stakeholders.

Here are a few excerpts from an interview he participated in with the Wall Street Journal.  It was published on May 23, 2012.

WSJ:  What were the biggest disagreements with Walgreen?
Mr. Paz:  I should only be paying for things that matter.  I shouldn’t be paying for things that don’t matter.  And, if Walgreen wants a premium, and they’re not doing anything different, why should I pay them more?  One of the issues was the way Walgreen defined generic drugs.  That would have been a billion dollar effect on my book of business.  That would’ve been a huge windfall back to Walgreen that doesn’t exist in any of my other [pharmacy] contracts.

[Regarding paying a premium, a Walgreen spokesman said virtually all other payers see that we are in line with the market and have us in their networks.”  On generics, the spokesman said that “Express Scripts insisted on being able to unilaterally define contract terms, including what does and does not constitute a brand and generic drug.”]

WSJ:  Talk about the role pharmacists should play in healthcare.
Mr. Paz:  I said one time that it shouldn’t matter who counts to 30 for filling up retail prescriptions, and I caught a lot of grief for that, and probably rightfully so. But that wasn’t the point.  The point is that putting pills in a bottle doesn’t change health outcomes.  It doesn’t matter whether you get your pills at Walgreen or CVS or Kroger.  The reality is:  What happens with that process?  Who is taking care if that patient?  It’s not counting pills and sticking them in bottles.  That doesn’t add any value.

WSJ:  How does Express Script use its pharmacists?
Mr. Paz:  I’ve taken those pharmacists and asked them to reach out to doctors.  Doctors still misprescribe very often.  They leave gaps with care.  People with asthma, they they don’t take their inhalers, they wait until they’re sick, and by then, it’s too late.  Now we’re already running up the bills and going to the emergency rooms.  We’re using our pharmacist to do the things they were educated to do, not to count pills.  That’s not where the value is.

WSJ:  How might the company’s size help drive down healthcare costs for individuals?
Mr. Paz:  Medicare and Medicaid costs are skyrocketing.  The cost of compliance with some pretty tough rules has become very costly.  If I’m small, I have to spend the same amount of money to comply with Medicare, whether I’m 10 members or I’m 10 million.  By creating size and scale, I can spread those covers over more and more people, and therefore lower the costs per person.

There are so many contradictions in these statements I don’t even know where to begin.  First, he talks about paying only for things that matter.  Well I’ve repriced more than enough of Express Scripts claims data to know that his clients are, in fact, paying far too much for things that don’t matter.

And you’re using pharmacists to call doctors at $55/hr?  Primary Care Physicians are extremely busy and it takes several call backs to reach them.  They don’t want too hear anyone tell them about their gaps in care especially a PBM that restricts their prescribing options.  This is a waste of time and money.  Particularly, when you consider the increasing popularity of e-prescribing.  Sounds to me like Express Scripts is searching for a reason to charge more for their service even when it doesn’t add value.  Control what you can control by implementing more compliance packaging, for example.

Furthermore, if Walgreen’s, one of the largest pharmacy chains in the world, statement is even partly true with regard too Express Script’s desire to unilaterally determine contract language then where does that leave a small to midsize company?  No chance to not pay for things that don’t matter is what’s left for smaller companies dealing with Express Scripts.

There is so much incentive provided in this interview for payors to re-evaluate their pharmacy benefit. But, unfortunately most won’t.  Who cares if your PBM account manager and/or consultant is telling you it’s raining outside when really they’re peeing down your back. George Paz said, “our size should help drive down costs for consumers.”  Before the merger was approved it was, “will drive down costs for consumers.”

I’m not saying that ESI doesn’t provide a good service.  Instead, I’m saying that their customers aren’t being educated and as a result are paying far too much for similar services they could get for 20 to 30% less. You could be saying too yourself who am I too judge the CEO of a fortune 50 company. He must be more intelligent, trustworthy and industrious compared to the owner of a boutique PBM, right?  I’ve got two words for you – George Bush.

Out-of-Network Benefits, the One–Two Punch

Today, most health plans have one level of benefits for care rendered by an in-network provider and a lower benefit for services from an out-of-network provider.  Insurance carriers encourage use of in-network providers because doing so helps control claim costs.

In-network providers have contracted with the insurance companies to provide medical care at reduced prices.  In exchange, the insurance companies direct patients to the in-network providers. The arrangement increases business for the providers and decreases claims cost for the insurance company.

Treatment out-of-network is a different story. Out-of-network providers have no agreement or incentive to reduce prices and control cost.  At times, however, they may provide a level of care or service that a particular patient needs or wants.  Patients seeking care out-of-network need to be aware of the way their benefits will be calculated.

There is more to it than the out-of-network deductible and co-insurance. Insurance policies have clauses and exclusions against treatment that is not medically necessary.  There are also provisions that the carrier only allows the Usual, Customary, and Reasonable (UCR) charge for a service provided.

Over the last few years, many carriers have begun to define their allowable charge or UCR limit as the amount negotiated with in-network providers. The difference can be substantial. For instance, if the retail price of a surgery is $4000, the discounted amount could be $2500, a $1500 discount.  If in-network benefits are paid at 80%, the patient would owe $500 for the surgery (20% of $2500). A patient receiving care out-of-network would not receive the benefit of the discount.

Out-of-network benefits may be paid at 60%. The patient’s responsibility is 40% of the UCR amount of $2500 or $1000, plus the difference between retail and the UCR amount ($4000 – $2500) or another $1500.  The total owed by the patient would be $2500 on a $4000 surgery.

To avoid surprises, it is important that your employees understand how out-of-network benefits are calculated.  Some providers will agree to write off all or part of the balance.  A financial agreement before receiving services is critical.  After services are rendered, many providers are not willing to discuss discounts.

Physicians Evaluate PPACA

Physicians’ political views on healthcare reform vary widely, but the findings of a recent survey by Jackson Healthcare show that many agree on at least one thing:  PPACA does not sufficiently reform the U.S. healthcare system. Jackson Healthcare conducted an online national survey of physicians to ascertain whether respondents believe PPACA effectively addressed previously stated physician concerns about healthcare reform. Those concerns, identified in earlier physician surveys by Jackson Healthcare, were stated as such:

  • Defensive medicine is a key driver of the ever-expanding cost of U.S. healthcare
  • Defensive medicine has important effects beyond cost
  • Tort reform fails to reduce the practice of defensive medicine

1,440 physicians completed the latest survey. Analysis of the responses indicates physicians do not believe PPACA provides the necessary reforms to alleviate their concerns and they gave PPACA an average grade of D.

Key Findings:

  • Nine out of ten physicians do not believe PPACA provides effective reform
  • 38 percent believe PPACA did nothing to reform the healthcare system
  • 31 percent believe PPACA did not go far enough
  • 22 percent believe PPACA went too far and will impede physicians’ ability to practice medicine
  • 52 percent of physician respondents believe PPACA will negatively affect their practice through    decreased reimbursements, revenues and longer work days
  • 20 percent of physician respondents believe PPACA will positively affect their practice as more patients access care and the number of no-pay cases decreases
  • 11 percent of physicians are making changes to their practices in response to PPACA, including EMR / HER implementation, changing careers / retiring, opting out of Medicare / Medicaid

Physicians are equally divided on whether PPACA should be repealed (52 percent in favor of repeal
vs. 48 percent).

HSA Qualified Medical Expenses: Confusion between 502 and 213

Confusion exists about what is a qualified medical expense for Health Savings Account (HSA) withdrawals.  Different government sources refer to IRS codes sections 502 and 213, as do industry sources.  Consumers want a list of qualified medical expenses yet no one, not even the government, is willing to commit in writing.

I will attempt to clarify this confusing HSA issue. The Treasury Department has released guidance for HSA implementation and use.  Treasury Notice 2004-2 was issued to clarify HSA rules and issues. Answer 26 of the guidance states “qualified medical expenses are expenses paid by the account beneficiary, his or her spouse or dependents for medical care as defined in Section 213d but only to the extent the expenses are not covered by insurance otherwise.”

This seems clear enough.  So where does the 502 language come into play? IRS Publication 969 (instructions for HSAs) says that qualified medical expenses are explained in Publication 502. I believe 213 and 502 provide essentially the same guidance to HSA beneficiaries. Internal Revenue Code 213d is the actual code section dealing with the definition of medical expenses. IRS Publication 502 is the tax filing instructions when claiming medical and dental expenses on your tax return. Publication 502 is a summary of IRC 213 and is more simply written.

Hopefully, this provides some clarification on this matter.  The aforementioned is my opinion; I cannot render tax or legal advise.  Please consult your attorney or tax advisor to review the facts and circumstances of your particular case.

U.S. Health Insurers to Reimburse $1.3 Billion

U.S. health insurers will pay $1.3 billion in rebates to consumers and employers this year under a provision of President Barack Obama’s healthcare reform law that penalizes plans that devote too little of their premium revenues to health services, an independent study showed on Thursday.

The study, published by the nonpartisan Kaiser Family Foundation, said the data illustrated some of the tangible benefits that consumers and employers could expect from the embattled 2010 reform law if it survives two major legal and political election-year challenges.

Under the law, called the Patient Protection and Affordable Care Act, health insurers must spend at least 80 percentage of premium revenues on health expenses and quality improvements. The rule is intended to limit the amount the $850 billion health insurance industry devotes to marketing, administration and profits.

Kaiser, a nonprofit healthcare research group, found that 31 percent of consumers in the individual insurance market could expect to receive a total of $426 million in rebates on 2011 premiums, for an average of $127 per person.

About 20 percent of the insurance industry’s market for large employers could receive $541 million, while more than one-quarter of the small group market that serves small businesses could look forward to rebates totaling $377 million. The rebates are due by Aug. 1 and most of the money is expected to go to employers rather than consumers.

The healthcare law has proved unpopular with many voters and could be struck down by the U.S. Supreme Court by the end of June or repealed next year if Republicans gain control of the Congress and White House in the November election. If the high court overturned the law, insurers would no longer be required to comply with the rebate provision.

A main target for public dislike is a reform provision that requires most Americans to buy private health insurance by 2014 as part of a plan to extend health coverage to more than 32 million people who are uninsured.

Reform advocates insist that much of the public’s dislike for the law stems from a lack of knowledge about the advantages it offers to consumers and others.

Some of the biggest rebate payouts are expected in states, including Texas and Florida, where the reform law faces some of its stiffest opposition from Republican politicians and other conservatives.

“While the health reform law as a whole continues to divide the American public, there are tangible changes taking place that benefit consumers,” said Kaiser President Drew Altman.

“Greater regulatory scrutiny of private insurance is improving value and helping to get excess costs out of the system,” he added.

The Kaiser study is based on insurer filings to the standard-setting National Association of Insurance Commissioners and includes rebates already paid and insurer estimates of planned payments on 2011 premium revenues.

Dig Deeper: Don’t be Fooled by Fancy Titles and Terms

Simply put, panflation refers to the devaluation of everything.  Stay with me here.  I’m going to make some specific points that relate to your everyday life. Then I’ll bring it home with some very specific references to the pharmacy benefit management industry.  Panflation is influencing plan sponsor behavior.

Take the rarely reported issue of  “name inflation.”  There was a time when a platinum credit card meant something.  You were someone who always paid bills on time, made a bit more money then the average consumer and had proven it over time.  It made you feel special. That you were being rewarded for your diligence. Now, even if one has bad credit he/she can qualify for a platinum credit card. The exclusivity of the platinum credit card has been devalued, but some consumers have yet to recognize this trend.  The travel industry is notorious for such hyperbole.

Many hotels no longer offer standard rooms, but instead offer deluxe rooms. How many times have you booked a superior or deluxe room at a hotel only to be disappointed upon check-in?  You walk into the hotel room and the view is of a brick wall. There is hair in the sink and the room smells like cigarette smoke. Webster’s dictionary clearly states that superior means, “above the average in excellence or of higher grade and quality.”  Inflating terms is a tool the travel industry utilizes to lure unsuspecting customers into making a purchasing decision.  The travel industry is not the only participant in this plague.

Next, let’s look at the rarely reported problem of “title inflation.” It seems as though everyone today is an expert, consultant or specialist.  When confronted with an important decision most of us tend to rely on these so called experts to help guide us through difficult processes. Sometimes we rely too heavily on people based solely upon a title. In most professions, excluding the obvious like a physician or lawyer, there is no special training required in order to be labeled as an expert or consultant. The PBM industry is notorious for this sort of title inflation.

I recently spoke with a benefit consultant from a reputable consulting company not to long ago. Our business together involved a client of hers seeking to reduce prescription drug expenses. Upon conclusion of our re-pricing analysis the results were presented and the savings substantial.  She proceeded to ask,”how am I able to determine if a PBM is fully transparent?”

When she posed this question I was both befuddled and disturbed at the same time. Her client is relatively large at almost 60,000 scripts per year and was grossly overpaying for its pharmacy benefit. They are relying on you [firm] to protect them, but you can’t even though you’re an “expert.”

Plan sponsors must make sure to have a basic understanding of pharmacy benefit management.  It takes some time, but not much.  Participate in webinars and read a blog or two for the most recent industry best practices. Then hold your PBM and its employees accountable by testing them.  If they don’t have the requisite knowledge why are you retaining them? In the healthcare industry, digging a bit deeper than all the hyperbole being offered on the surface may very well save your company quite a bit of money and time.

Informed Health Care Decisions Cut Costs & Saves Lives

All too often, employees are forced to make important choices that can affect their family’s health and health-related financial security. Making these decisions can be stressful and confusing; especially when a family member is ill or when considerable medical expenses are involved.

That’s why many insurance companies now provide treatment cost estimators which provide an easy way to see how much certain procedures and services will cost before a visit to a provider. Armed with this information, employees can make cost effective choices and more informed decisions.

Knowing the costs upfront is important due to their responsibility for paying a portion of their health care costs. And it’s helpful for budgeting aspects of their health benefits and health insurance plans, such as health savings accounts and flexible spending accounts, or for seeing how quickly they may reach their deductible and coinsurance limits.

Employees will need to create a login to their insurance company plan to access these tools. Also, it is important to note that some carriers’ sites display rates billed by the providers and others display the contracted, negotiated rates for in-network providers.

As of this posting, Medical Mutual, Aetna, and United HealthCare use the negotiated rates in their illustrations. However, Anthem uses only the rates billed by the provider, which may not provide an accurate picture to employees about their actual costs.

PPACA: What Will the Supreme Court Decide?

In late March the Supreme Court took the somewhat unusual step of setting aside three days on its calendar just to hear the various aspects of the Constitutional challenge to the Patient Protection And Affordable Care Act. The schedule affirms the universal expectation that the court will issue a ruling on the healthcare law in June, at the height of the 2012 campaign. The Supreme Court sessions began with one hour of arguments on whether it can reach a decision on the reform law before 2014.

There is a possibility that a separate federal law will prevent the courts from ruling until the law’s individual mandate has taken effect. The justices then heard two hours of arguments on the core question of whether the mandate is unconstitutional. And, finally, the court heard two and half hours of arguments on two issues: how much, if any, of the law’s other provisions can be upheld if the mandate is unconstitutional, and whether the health law’s Medicaid expansion is constitutional. There hasn’t been another case in recent memory that’s been argued on this kind of schedule. It no doubt reflects the Court’s own recognition of the complexity and importance of the issues involved.

SBC: Summary of Benefits and Coverage

The Departments of Health and Human Services, Labor, and Treasury, have issued the final regulations for the Summary of Benefits and Coverage. To help consumers better understand and compare health plans, insurers and group health plans are required to provide a new, uniform way to show benefits and define health care industry terms. The effective date for providing the SBC begins on September 23, 2012. Of course, the Supreme Court decision could affect this requirement.

The Signed Waiver: Important Protection

Most employers have some people in their workforce that do not need or want benefits for various reasons. Much of the time it is because they are covered by their spouse’s health insurance plan; although, other reasons do exist.

If your company has employees that are eligible to participate in the health insurance plan but have chosen not to for any reason, we suggest that you have them sign a “waiver of participation” form. This form is generally provided by your insurance carrier and normally is required to be completed by non-participating employees.

The signed waiver is your only protection against allegations that you did not offer coverage to an employee. The question of whether or not you allowed the employee to participate can easily be proven if you have a waiver that has been signed by the employee. Of course, this is not an allegation that comes up often. When it does, it is usually because there are outstanding claims and no insurance to cover them. This is a liability that most employers are not interested in self-insuring. A properly signed waiver is the best protection against this happening to your company.

Express Scripts & Medco Merger Approved, Now What?

For the record I was an opponent of the Express Scripts (ESI) and Medco merger.  The FTC, in a 3 to 1 vote, has determined that the merger doesn’t violate antitrust laws thus permitting it to move forward. The two behemoth PBMs quickly completed the merger today.  Let’s examine the impact on stakeholders in the U.S. pharmaceutical supply chain:  manufacturers, pharmacies, payors, and patients. 

From Wikipedia, A true duopoly (from Greek duo δύο (two) + polein πωλεῖν (to sell)) is a specific type of oligopoly where only two producers exist in one market. In reality, this definition is generally used where only two firms have dominant control over a market. In the field of industrial organization, it is the most commonly studied form of oligopoly due to its simplicity.”

The merger of ESI and Medco essentially creates a duopoly.  Combined with CVS/Caremark, the nation’s second largest PBM, the two companies account for 73% of all prescriptions dispensed in the USA. Pharmaceutical manufacturers eager to place expensive brand prescription medications onto PBM formularies will experience more pressure from ESI to increase rebates and lower prices.  

 
If you’ve read all my previous posts then you know rebates from manufacturers to PBMs take on many names and sometimes aren’t even classified as rebates, but instead as reimbursements.  The point is that any money (rebate) paid out by a manufacturer to a PBM is due solely to the PBM’s huge patient database therefore100% of those rebates should go back to the payors [whom fill these databases with patient lives]. I’ll discuss this more in a bit. 
 
Some pharmacies, like manufacturers, will experience increased pricing pressure from the largest PBM in the USA.  Prior to the approved merger ESI had already flexed its muscle with Walgreen’s. The two companies weren’t able to agree on reimbursement rates.  ESI proposed to lower rates. Walgreen’s was resistant to adhere to ESI’s pricing pressure at least until now.  I expect Walgreen’s has reluctantly swallowed their pride and is currently on the phone to ESI begging for the deal it initially shot down.  Good luck with that!   
 
Chain pharmcies will not be the only class of trade to take a hit in this deal.  Independent pharmacies, including mail-order, specialty and retail, will see EBITDA decline.  Pharmacies are reimbursed, by PBMs, based on a pre-determined pricing contract.  I can tell you as an independent pharmacy owner these reimbursements are too small and will get smaller.  
 
I’m not a greedy business owner.  I run a tight ship and focus unforgivingly on waste elimination.  I expect only a fair return.  Because of my experience working for Eli Lilly and Co. I know how expensive it is to bring a new drug to market and just as important how little it costs, relatively speaking, to manufacture the drug after FDA approval.  A pharmaceutical manufacturer can easily realize an 80% gross margin. 
 
For example, a 90-day supply of Actos cost us approximately $530.00.  We consider ourselves fortunate if a PBM reimburses us $550.00 (plus a $25 patient co-pay) for dispensing this medication to a plan participant.  In other words, don’t shoot the messenger!  The next time you have a complaint about rising drug costs it’s not your pharmacist’s doing.  
 
Nothing pains me more when I read about the CEO of ESI, George Paz, expressing how much patients will benefit from this merger.  Really?  Employers, federal and state governments capitalize the U.S. pharmaceutical supply chain not patients.  The health insurance marketplace, unlike most marketplaces, is one in which the end user or beneficiary doesn’t carry most of the financial burden.  
 
Payors or plan sponsors have to “get smart” about their pharmacy benefit.  Now more than ever the focus must be put on 100% transparency. Buyer beware, there is not a PBM on the planet that won’t say it’s 100% transparent.  Transparency is not created equally.

With the help of a really good consultant, define transparency internally. Then hold potential suitors accountable too it and don’t waiver a single inch.  If the relationship falls short of your definition of 100% “true” transparency then find a new partner.  The very large and smart payors may very well benefit from this merger.  

 
A very large and smart employer (25,000+ lives) may experience a rebate increase while drug costs could decline.  This is true only in the case ESI passes all the savings on to its very large customers. Smaller and less knowledgeable payors might see no change at all or worse see an increase and basically be told take it or leave it.  Be sure to hire a brilliant team of consultants to work on your behalf and help determine which side of the fence you’re on.    

A Cobra Exemption…

Employers who had fewer than twenty full-time employees on fifty percent of the business days in the previous calendar year are exempt from the federal requirements of COBRA. Based on your company size, you may need to annually review your need to comply with COBRA in each calendar year.

All full-time and part-time employees are counted when determining if an employer had at least twenty employees in the previous calendar year. Part-time employees are counted as fractions of full-time employees based on the number of hours worked by full-time employees in that business. For example, if a full-time employee normally works a 6-hour day, then two part-time employees working three hours a day equal one full-time employee. Additional guidance and rules apply.

— Claim Problems —

Insurance carrier claim processors all too often look for reasons to deny a claim. At TransparentRx the mindset is different. We look for ways to get claims paid; thereby, satisfying your employees with the outcome. We don’t win every dispute, but we are successful much of the time. We encourage you or your employees to contact your broker if you’re experiencing claim difficulties.

— Dropping Coverage in Anticipation of Divorce —

Q: If an employee drops coverage on his spouse during open enrollment and the reason he is dropping her is in anticipation of a divorce, what are the requirements of the plan offering her COBRA coverage? Are there employer obligations regarding dropping the spouse’s coverage?

A: Yes. If coverage is reduced or eliminated in anticipation of a COBRA qualifying event, and the individual whose coverage was previously terminated or reduced is considered eligible for COBRA at least as of the qualifying event, the spouse must be offered the coverage, effective at least from the date of the qualifying event, which in this case is the divorce.

The final COBRA rules note that if an employee cancels a spouse’s coverage in anticipation of divorce or legal separation, “Upon receiving notice of divorce or legal separation, a plan is required to make COBRA continuation coverage available, effective on the date of the divorce or legal separation (but not for any period before the date of the divorce or legal separation).

— Small Business Health Care Tax Credits —


The new health reform law gives a tax credit to certain small employers beginning with the 2010 tax year. To be eligible for the credit, an employer must be a “qualified employer”. This means you must:

1. Provide qualified health insurance to employees.
2. Employ fewer than 25 full-time equivalent employees (FTE).
3. Have average annual wages of less than $50,000 per full-time equivalent employee.
4. Contribute a uniform percentage (not less than 50%) of the cost of single coverage.

The maximum credit is 35% of the employer’s share of the premium cost in 2010-2013. Employers with more than 10 FTEs and/or average wages in excess of $25,000 begin to proportionally lose the tax credit.

In 2014 the tax credit is 50% and can be claimed for any two years. In 2014 and beyond, the tax credit is contingent upon dropping existing coverage and purchasing group coverage from a newly created exchange (government created purchasing co-op).

TransparentRx thinks it is important for employers to study and understand this section of the code, since some planning opportunities exist that could help them qualify for the maximum credit available. The availability of the Small Employer Tax Credit may encourage some employers to proceed with additional layoffs or terminations and to halt any plans to add employees in order to maximize their tax credit.

Below is a link to the IRS Website regarding the Small Business Tax Credit:
http://www.irs.gov/newsroom/article/0,,id=220839,00.html

In a RFP the Whole is Greater than the Sum of its Parts

Gestalt theory suggests that the “whole is greater than the sum of its parts.” In other words, each individual working part of a team, a piece of equipment or even a contract is less significant than the results achieved when these parts are combined for one well-defined goal.  Plan sponsors and their agents tend to take the opposite approach when evaluating PBM proposals.  There are three key areas for improvement most plans sponsors can take advantage of in their RFP process: designevaluation and compensation.

In most RFP processes conducted by brokers or HR generalist consultants, they simply send out the request, get the top three bids and ask you, the payor, to select the vendor with the lowest price points.  The big problem here is that in most cases the price points for which your decision is based are often perceived and not real.  In fact the prices are often trivial!  As a payor your questions should be…

 
1.  On whose behalf is my agent negotiating with other PBMs; mine or their own?
2.  What are my actual costs?
3.  Based upon my key performance factors, is this really the best deal?
Perhaps you have experienced this situation.  You believe the deal with your broker consultant is great because you don’t compensate them directly.  Further yet you believe the consultant will always work in your best interest.  Is it feasible to believe that in a capitalistic society when someone else is footing the bill a sales-based organization is more loyal to the non-paying party?  Maybe you believe so personally I don’t. 
 
Early renewal is a logical alternative to conducting an arduous RFP process.  It is very tempting to use an incumbent broker or consultant for the entire RFP process.  However, it is very challenging, at best, to distinguish the difference between your existing consultant and the PBM due to what I consider conflicts of interests.  Identify 8 -10 key performance factors and focus on these during your evaluation process.  Don’t be impressed by 50 page RFPs.  They often contain requests for information that are commonplace in the industry and simply waste everyone’s time.  You’ll understand why in bit. 
 
Your consultant will seek bids from vendors other than the one promoted in their coalition.  However, they will only receive a “management fee” if you select their program.  Many plan sponsors would be surprised to learn the actual costs of their PBM program.  You are “footing the bill” regardless of what you’ve been told.  Your consultant’s “management fee” is being factored back into the cost of your plan whether you know it or not.
Ultimately, you want the plan that will produce the lowest net cost, not the highest rebates.  If a consultant offers you an unusually low fee or no fee to conduct your procurement, ask yourself whose interests they truly represent.  I suggest you use an independent firm focused on getting the “right” arrangement for you from whichever PBM is the best fit.